Ovarian cancer is the second most common gynecologic cancer among women and the second leading cause of death from gynecologic malignancy worldwide. Androgens, acting through androgen receptors (ARs), have been implicated in the disease, while progestins, acting through progesterone receptors (PGRs), may provide protection against the disease. The PGR gene contains several polymorphisms in the hormone-binding domain, three of which are in linkage disequilibrium (a complex referred to as PROGINS). PROGINS has been associated with increased risk of ovarian cancer. This association has not been found consistently, and it may be limited to women who do not use oral contraceptives. The AR gene contains a trinucleotide CAG repeat, the length of which has been inversely associated with the ability of the AR-ligand complex to transactivate androgen-responsive genes. Data on the association between the AR repeat length and ovarian cancer, both in general and among carriers of mutations in the breast cancer 1 and 2 (BRCA1/2) genes, are inconclusive. There is insufficient evidence that polymorphisms in either the PGR gene or the AR gene may be a risk factor for ovarian cancer, alone or in combination with other factors. The sensitivity, specificity, positive and negative predictive values, and clinical validity of the PROGINS and AR CAG repeat assays are unknown. No recommendations for population-based screening can be made.

**Abbreviations:** AR, androgen receptor; BRCA, breast cancer; CI, confidence interval; OR, odds ratio; PCR, polymerase chain reaction; PGR, progesterone receptor.
a better prognosis (4). Epidemiologic data support the possibility of an inverse association of progesterin levels with ovarian cancer. Oral contraceptives, which are associated with reduced risk of ovarian cancer, increase progesterone levels in vivo (5). Progestin-only oral contraceptives are as protective against ovarian cancer as estrogen-progestin formulations (6), and high-dose progestin oral contraceptive formulations may be more protective against the disease than low-dose formulations (7). Together, these data suggest that it is the progestin component of oral contraceptives that provides, at least in part, the protective effect. Finally, progestin-containing hormone replacement formulations used in a continuous regimen have recently been shown not to be associated with increased ovarian cancer risk, whereas estrogen-only formulations and formulations in which the progestin component of oral contraceptives was used sequentially were both associated with increased risk (8).

There is also emerging evidence that androgens may be associated with ovarian cancer risk (see review by Risch (1)). Androgens are produced by ovarian theca lutein cells, are present in ovarian follicular fluid, and are the principal sex steroid of growing follicles (9). Androgen receptors (ARs) are found in the normal surface epithelium of the ovaries (10), suggesting that androgens are active in the organ. Interestingly, the postmenopausal ovary is androgenic (11), as evidenced by 15-fold higher testosterone concentrations in the ovarian vein in comparison with serum from peripheral veins (11). Most ovarian cancers express AR, and antiandrogens inhibit ovarian cancer growth (12, 13). Epidemiologic evidence supports the possibility of an androgen-ovarian cancer link. Oral contraceptives, the most effective chemopreventive agent against the disease, suppress ovarian testosterone production by 35–70 percent (14–18). A prospective study (19) found significantly higher levels of androstenedione in the serum of case women than in control women. In the Cancer and Steroid Hormone Study, case women were more likely to have a history of polycystic ovary syndrome (odds ratio (OR) = 2.4, 95 percent confidence interval (CI): 1.0, 5.9) (20), a condition that causes androgens to be associated with increased ovarian cancer risk, whereas estrogen-only formulations and formulations in which the progestin component was used sequentially were both associated with increased risk (8).

In contrast, there is evidence that the AR gene may have an ovarian tumor suppressor function. AR mRNA and protein are down-regulated in ovarian cancer (10, 34). Moreover, loss of heterozygosity in the region containing the gene has been reported in approximately 40 percent of ovarian cancers (35–37). Finally, nonrandom X-inactivation (38) has been reported in invasive ovarian cancer (39), with expression potentially favoring the allele producing the less active receptor protein (40).

**Progesterone receptor**

The physiologic effects of progestins depend on the presence of human PGR, a member of the steroid-receptor superfamily of nuclear receptors (41). The PGR gene is located at 11q22-q23 (42–45). PGR exists in two isoforms produced by the single gene with two different promoter and translational start sites. PGR-B is the full-length receptor, while PGR-A is missing the first 165 amino acids (46, 47). The PGR protein consists of an amino-terminal domain containing a ligand-independent activation function; a DNA-binding domain and hinge region in the central part of the protein; and a carboxy-terminal, ligand-binding domain containing a second activation function that is ligand-dependent (48). Although PGR-A and -B share these structural domains, they function as two distinct transcription factors (49) with distinct physiologic effects (50, 51). PGR-A has been shown to repress estrogen receptor and PGR-B gene activation, whereas PGR-B is a stronger activator of progesterone target genes (52).

**Androgen receptor**

Androgens exert their effects by first binding to ARs, members of the steroid hormone-thyroid hormone-retinoic acid family of nuclear receptors (48, 53). The resulting hormone-receptor complex then binds directly to DNA, thereby transactivating androgen-responsive genes. The AR gene, also known as dihydrotestosterone receptor, is located at Xq11.2-q12. It spans more than 90 kilobases and contains eight exons (54, 55). The AR protein consists of a highly acidic amino-terminal domain, which functions in transactivation and is located entirely in exon 1 (1,586 base pairs) (56); a highly conserved, cysteine-rich DNA-binding domain containing two DNA-binding fingers located in exons 2 (152 base pairs) and 3 (117 base pairs), respectively; and a mostly hydrophobic carboxy-terminal ligand-binding domain located in exons 4–8, which vary in size from 131 base pairs to 288 base pairs (57–60). The AR gene shares significant homology with both the estrogen receptor and PGR genes (54, 55, 61).

Two isoforms of AR have been identified in a variety of human tissues (62, 63). The two isoforms of AR are remarkably similar in structure to the A and B isoforms of PGR (62). AR-B is the full-length receptor, while AR-A lacks the normal N-terminus (62, 63). AR-A is derived from internal translation initiation at methionine-188 in the AR open-reading frame and usually constitutes 20 percent or less of the immunoreactive AR present in any tissue (64). Despite the differences in structure and abundance, the two isoforms do not appear to differ in their regulation or in their ability to bind with ligands and activate target genes (64).

**GENE VARIANTS**

**PGR gene**

Several polymorphisms in the PGR gene have been identified (65). A TaqI restriction fragment length polymorphism in the hormone-binding domain was the first one reported (66). The polymorphism is the result of a small 309-base-pair Alu direct repeat insertion inherited in a Mendelian fashion (67). Although the functional significance of this insertion remains unknown, it may have consequences for the integrity of the regulatory functions of the gene. Hormone binding and subsequent transcriptional activation by PGR depend on the presence of a complete and intact hormone-binding domain.
Alteration of part of this region induces a loss of hormone binding and transcriptional activity in vitro (68), as does the alternative splicing that may result from the Alu insertion (69). The Alu insertion has been associated with endometriosis (70) and breast cancer (71), both of which may be risk factors for ovarian cancer (72–81).

Two other polymorphisms, the Val660Leu polymorphism in exon 4 and the C→T Hist770Hist polymorphism in exon 5, are in complete linkage disequilibrium with the Alu insertion (65). Together, these three polymorphisms form a complex referred to as PROGINS (82). Recently, a fourth polymorphism, S344T, was reported (65), which was shown to have a standardized pairwise linkage disequilibrium ($D' = 0.99$) with the PROGINS polymorphisms. This new single-nucleotide polymorphism in conjunction with the other three polymorphisms creates a linkage disequilibrium region of approximately 75 kilobases (65), which is consistent with the observed average length of linkage disequilibrium in US populations of Northern European descent (83).

Other single-nucleotide polymorphisms in the PGR gene have been identified, including two variants in the coding region (S344T and G393G) and two in the promoter region (+44C/T and +331G/A) between the PGR-B and PGR-A transcriptional start sites (65). Interestingly, the +331G/A polymorphism creates a unique transcription start site and increases transcription of PGR, favoring the B isoform. Recently, the +331G/A polymorphism was found to be associated with endometrial cancer (65). No associations between the S344T, G393G, and +44C/T variants and endometrial cancer were found (65). To our knowledge, no studies have investigated these four PGR polymorphisms within the context of ovarian cancer.

Table 1 presents frequencies of the PROGINS alleles by ethnicity among relevant studies detected in a Medline search of articles published between January 1, 1990, and March 30, 2003. We combined searches for the keywords “progesterone receptor,” “polymorphisms,” and “ovarian neoplasms” to identify relevant studies. We further searched the references of any identified paper to locate additional studies. Only four studies identified (40, 97–99) have examined AR frequency: two Italian studies, one US study of Ashkenazi Jewish women, and one Australian study. Among the four studies, only two were case-control in design (40, 97). The remaining two studies (98, 99) were of case series. The mean length of the short AR repeat ranged from 17.0 to 20.5 repeats among women with ovarian cancer, and was 20.3 repeats among healthy control women from both case-control studies. The long AR repeat length ranged from 20.7 to 23.4 repeats among cases and from 22.8 to 23.6 repeats among controls. In the two studies conducted in Italy (40, 99), the mean number of long AR repeat lengths among cases was almost identical (23 vs. 23.4), while the mean number of short repeats was similar (19 vs. 20.3). The concordance of the findings of these studies, conducted by different investigators in different geographic locations in Italy, suggests that the findings are representative of Italian women with ovarian cancer.

DISEASE

Ovarian cancer incidence and mortality

In 2000, the worldwide incidence of ovarian cancer was 192.4 per 100,000 women, making the disease the sixth most common cancer among women (100). Worldwide, the highest incidence rates are found among White women in Europe and North America, and the lowest incidence rates are found in Asia. Rates in Central and South America lie

Am J Epidemiol 2004;159:319–335
between the two (101). In 2003, approximately 25,400
women in the United States will be diagnosed with ovarian
cancer, accounting for almost 4 percent of all cancers in US
women (102). From 1992 to 1999, the age-adjusted inci-
dence rate among US women was 17.1 per 100,000 (103).
The age-adjusted incidence rates for Caucasians, Hispanics,
### TABLE 2. Results of studies of androgen receptor gene polymorphisms and epithelial ovarian cancer, 1995–2003

<table>
<thead>
<tr>
<th>Study</th>
<th>Location/ethnic group</th>
<th>Description</th>
<th>Cases Controls</th>
<th>No.</th>
<th>Description</th>
<th>Cases Controls</th>
<th>No.</th>
<th>Short allele (mean, 95% CI)</th>
<th>Long allele (mean, 95% CI)</th>
<th>Average of alleles (mean, 95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levine et al., United States—New York City Ashkenazi Jewish women</td>
<td>N/A*</td>
<td>Consecutive Ashkenazi Jewish patients with pathologically confirmed invasive epithelial ovarian cancer from a single hospital diagnosed over a 12-year period that was genotyped for the 185delAG and 5382insC mutations in the BRCA1 gene</td>
<td></td>
<td></td>
<td>Age range, 30–79 years; mean age, 55 years for BRCA1 carriers</td>
<td></td>
<td>179</td>
<td>17.2 (3.3)</td>
<td>21.0 (3.3)</td>
<td>19.1 (2.8)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Age range, 25–87 years; mean age, 64 years for sporadic cases</td>
<td></td>
<td>85</td>
<td>17.0 (3.4)</td>
<td>20.7 (3.0)</td>
<td>18.9 (2.7)</td>
</tr>
<tr>
<td>Menin et al., Northern Italy</td>
<td>N/A</td>
<td>Ovarian cancer cases from “high-risk” breast/ovarian cancer families (defined as having three or more cases of breast and/or ovarian cancer on the same parental branch among first-degree relatives); age unreported</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>50</td>
<td>19.2 (2.5)</td>
<td>23.4 (2.7)</td>
<td>N/A</td>
</tr>
<tr>
<td>Spurdle et al., Australia</td>
<td>Control group 1: unrelated monozygotic female twins of European descent voluntarily registered in the Australian Twin Registry and participating in a study of the genetics of alcoholism, 1992–1996; controls were frequency-matched to cases by date of birth; age range, 30–90 years; mean age, 50.9 years</td>
<td>Incident cases of ovarian adenocarcinoma identified at a single hospital from 1985 to 1996; age range, 21–95 years; mean age, 59.8 years</td>
<td></td>
<td>300</td>
<td></td>
<td></td>
<td>319</td>
<td>20.5 (20.2, 20.8)</td>
<td>23.4 (23.1, 23.8)</td>
<td>22.0 (21.8, 22.2)</td>
</tr>
<tr>
<td></td>
<td>Control group 2: women without breast or ovarian cancer selected from the electoral roll by stratified random sampling and participating in a study of breast cancer; age range, 20–69 years; mean age not reported</td>
<td></td>
<td></td>
<td>553</td>
<td></td>
<td></td>
<td></td>
<td>20.3 (19.8, 20.9)</td>
<td>23.4 (23.0, 23.8)</td>
<td>21.9 (21.5, 21.9)</td>
</tr>
<tr>
<td>Santarosa et al., Italy 2002</td>
<td>Healthy female blood donors recruited from the same hospital as the cases; age range, 20–76 years; mean age, 40.1 years</td>
<td>Women with cases of ovarian cancer consecutively diagnosed at a single hospital from 1989 to 1996 (100 women)</td>
<td></td>
<td>100</td>
<td></td>
<td></td>
<td></td>
<td>20.3 (19.8, 20.9)</td>
<td>23.4 (23.0, 23.8)</td>
<td>21.9 (21.5, 21.9)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Women with consecutively diagnosed cases of ovarian cancer participating in a study of high-risk families (21 women); age range, 21–78 years; mean age, 54.2 years</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>20.3 (19.9, 20.7)</td>
<td>23.4 (23.3, 23.8)</td>
<td>21.9 (21.5, 21.9)</td>
</tr>
</tbody>
</table>

*Note: CAG repeat number and SD or 95% CI.*
Asians/Pacific Islanders, African Americans, and Native Americans/Alaskans were 18.1, 13.5, 12.6, 12.2, and 10.2 per 100,000, respectively (104). From 1989 to 1999, incidence rates declined by 0.7 percent per year (102). Although the rates among Asians and Hispanics in the United States are greater than the rates among women in Asia and Central/South America, they do not reach the rate of US Caucasians.

The lifetime risk of ovarian cancer in the population as a whole is approximately 1.4 percent. For women with a mutated BRCA1 gene, population-based studies estimate the risk to be 16–30 percent (105). Approximately 75 percent of women have advanced-stage disease at the time of diagnosis (102). Despite aggressive surgery and chemotherapy, the prognosis for these women is poor, with a 5-year survival rate of less than 40 percent (102). This outcome is due, in large part, to a lack of effective prevention and early detection strategies; with current treatment modalities, the survival rate is approximately 95 percent when this cancer is diagnosed at an early stage (102).

Ovarian cancer is surpassed only by cervical cancer as the leading cause of death from gynecologic malignancy worldwide, with a mortality rate of 114.2 per 100,000 women (100). In the United States, ovarian cancer accounts for 5 percent of cancer deaths among women and is the leading cause of death from gynecologic malignancy (106). In 2003, approximately 14,300 US women will die from the disease. The overall age-adjusted mortality rate in the United States is 9.1 per 100,000 (104), with the highest mortality rates being observed among Whites (9.4/100,000), African Americans (7.7/100,000), and Hispanics (5.8/100,000).

### Table 3

Association of the progesterone receptor gene PROGINS polymorphism with epithelial ovarian cancer in various studies

<table>
<thead>
<tr>
<th>Polymorphism and study</th>
<th>Subject population</th>
<th>Genotype</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>T1/T1</td>
<td>T1/T2</td>
<td>T2/T2</td>
<td>T2*/a</td>
<td></td>
</tr>
<tr>
<td><strong>Alu repeat insertion in intron G</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>McKenna et al., 1995 (66)</td>
<td>Pooled data</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of cases</td>
<td>43</td>
<td>23</td>
<td>1</td>
<td>24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of controls</td>
<td>146</td>
<td>33</td>
<td>5</td>
<td>38</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OR (95% CI†)</td>
<td>2.4 (1.3, 4.5)</td>
<td>0.7 (0.1, 6.0)</td>
<td>2.1 (1.2, 4.0)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Irish women</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of cases</td>
<td>26</td>
<td>15</td>
<td>0</td>
<td>21</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of controls</td>
<td>58</td>
<td>21</td>
<td>4</td>
<td>25</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OR (95% CI)</td>
<td>1.6 (0.7, 3.6)</td>
<td>1.3 (0.6, 2.9)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>German women</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of cases</td>
<td>17</td>
<td>8</td>
<td>1</td>
<td>9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of controls</td>
<td>88</td>
<td>12</td>
<td>1</td>
<td>13</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OR (95% CI)</td>
<td>3.5 (1.2, 9.7)</td>
<td>5.2 (0.3, 86.8)</td>
<td>3.6 (1.3, 9.7)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Manolitsas et al., 1997 (192)</td>
<td>No. of cases</td>
<td>173</td>
<td>52</td>
<td>6</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td>No. of controls</td>
<td>162</td>
<td>54</td>
<td>4</td>
<td>58</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OR (95% CI)</td>
<td>0.9 (0.6, 1.4)</td>
<td>1.4 (0.4, 2.6)</td>
<td>0.9 (0.6, 1.4)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lancaster et al., 1998 (85)</td>
<td>No. of cases</td>
<td>76</td>
<td>15</td>
<td>5</td>
<td>20</td>
<td></td>
</tr>
<tr>
<td>No. of controls</td>
<td>79</td>
<td>18</td>
<td>4</td>
<td>22</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OR (95% CI)</td>
<td>0.9 (0.4, 1.8)</td>
<td>1.3 (0.3, 5.0)</td>
<td>0.9 (0.5, 1.9)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Runnebaum et al., 2001 (186)</td>
<td>All BRCA1/2†-positive women</td>
<td>No. of cases</td>
<td>101</td>
<td>60</td>
<td>6</td>
<td>66</td>
</tr>
<tr>
<td>No. of controls</td>
<td>328</td>
<td>153</td>
<td>15</td>
<td>168</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OR (95% CI)</td>
<td>1.3 (0.9, 1.8)</td>
<td>1.3 (0.5, 3.4)</td>
<td>1.3 (0.9, 1.8)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OC† users</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of cases</td>
<td>54</td>
<td>23</td>
<td>1</td>
<td>24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of controls</td>
<td>236</td>
<td>122</td>
<td>12</td>
<td>134</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OR (95% CI)</td>
<td>0.8 (0.5, 1.4)</td>
<td>0.4 (0.05, 2.9)</td>
<td>0.8 (0.5, 1.3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OC nonusers</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of cases</td>
<td>47</td>
<td>37</td>
<td>5</td>
<td>42</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No. of controls</td>
<td>92</td>
<td>31</td>
<td>3</td>
<td>34</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OR (95% CI)</td>
<td>2.3 (1.3, 4.2)</td>
<td>3.3 (0.7, 14.2)</td>
<td>2.4 (1.4, 4.3)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table continues
Descriptive epidemiology

The most consistent protective factors for ovarian cancer are bearing children (107–126) and using oral contraceptives (107–114, 126–139). Tubal ligation and breastfeeding also appear to reduce risk (126, 140–142). Other factors shown to lower risk include physical activity (143), twinning (144), and the use of antiinflammatory agents, such as aspirin and the newer nonsteroidal antiinflammatory drugs (145), although data on these factors are inconsistent (145–154).

Age is an important risk factor for ovarian cancer. The disease is uncommon before age 35 years, and incidence steadily increases until about age 80 years (103). The most consistent risk factor for ovarian cancer is family history. Women with one affected first-degree relative have a 5 percent lifetime risk (1 in 20, versus 1 in 70 for the general population). Those with two affected first-degree relatives have a 7 percent risk (155). Three hereditary syndromes have been defined: the very rare Lynch Syndrome II, which is associated with defects in DNA mismatch repair genes and hereditary nonpolyposis colorectal cancer; and hereditary site-specific ovarian cancer and hereditary breast/ovarian cancer, both of which are associated with mutations in breast cancer genes 1 and 2 (BRCA1/2).

Other risk factors that have been less consistently associated with ovarian cancer include talc use (156), infertility (157), endometriosis (72), pelvic inflammatory disease (158), polycystic ovary syndrome (20), hormone replacement therapy (159), and central obesity (increased waist-to-hip ratio) (24). Cigarette smoking has also been shown to be a risk factor, but only for tumors of the mucinous subtype (160–163).

Genetic epidemiology

Approximately 5–10 percent of malignant epithelial tumors contain germline BRCA1/2 mutations (164–166),
most of which are found in BRCA1. Compared with sporadic disease, BRCA1/2-associated ovarian cancer is often diagnosed at a later stage (167, 168), although survival for BRCA1/2-associated disease appears to be better than survival for sporadic disease (167–169).

Approximately 1 in 800 women carries a BRCA1/2 mutation. In Ashkenazi Jewish women, the prevalence is about 1 in 50 (170–172). Among the Ashkenazim, approximately 45 percent of ovarian cancers arise from two BRCA1 mutations (185delAG and 5382insC) and a single BRCA2 mutation (6174delT) (173–176). These three mutations are commonly found in other ethnic groups. The penetrance of BRCA1 mutations for ovarian cancer is 36 percent by age 80 years (177) and may depend on the location of the mutation (178, 179). In general, the penetrance of BRCA2 mutations is lower than that of BRCA1 mutations (177), and an ovarian cancer cluster region has been identified (180, 181).

Among women carrying a mutated BRCA1/2 gene, childbearing (182) and tubal ligation (182) appear to be protective against the disease. Whether oral contraceptives afford the same degree of protection to carriers as they do to noncarriers remains controversial (182–184).

ASSOCIATIONS AND INTERACTIONS

**PGR polymorphisms and ovarian cancer risk**

Table 3 shows the reported associations of PGR polymorphisms with epithelial ovarian cancer in the seven studies identified in the literature. The first study (66), comprising a small convenience sample, suggested a possible increase in ovarian cancer risk associated with the PROGINS allele. However, more recent studies using larger data sets (84, 185) have failed to establish any statistically significant associations, and no consistent pattern of increased risk has emerged. Only one population-based study has addressed the question (84), with a modest association of borderline significance found only among women who had never used oral contraceptives (OR = 1.8, 95 percent CI: 1.0, 3.3; adjusted for age, tubal ligation, and race). A similar finding was reported among women with BRCA1/2 mutations (186).

There are several reasons for the negative findings. Small sample sizes limit the power of any one study; convenience samples may introduce bias into the study results; and selection of controls who are not representative of the population from which the cases were ascertained may generate selection bias. Data on other important factors, such as the response rates of cases and controls, were not reported in most of the published articles. This made it difficult to adequately assess other biases or flaws that may have been introduced into individual studies.

Several studies have examined the association of PROGINS with tumor behavior (84, 185, 187). No significant associations have been reported for tumor grade, stage, histologic subtype, invasiveness, or age at onset. Again, the small sample sizes and the limited details provided by the reports make it difficult to assess the validity of these findings.

**PGR polymorphisms, oral contraceptive use, and ovarian cancer risk**

No studies have investigated formal interactions between PROGINS and ovarian cancer risk factors. However, Runnebaum et al. (186) examined the association of PROGINS with oral contraceptive use and ovarian cancer risk among women with a BRCA1/2 mutation. They reported no association overall between disease status and the presence of the PROGINS allele and no modifying effect of PROGINS in women who reported ever using oral contraceptives. However, in women who had never been exposed to oral contraceptives, the presence of at least one PROGINS allele was associated with increased risk of ovarian cancer (unadjusted OR = 2.4, 95 percent CI: 1.4, 4.3). The association was even stronger (though not statistically significant) when the analysis was limited to women carrying two PROGINS alleles (unadjusted OR = 3.3, 95 percent CI: 0.7, 14.2). The authors reported a similar association after adjustment for year of birth and ethnicity. No other adjustments were mentioned.

Lancaster et al. (84) recently reported no association between PROGINS and ovarian cancer risk in general or among oral contraceptive users and nonusers. However, in their data set, the PROGINS allele was less common among cases who had ever used oral contraceptives in comparison with controls (OR = 0.8, 95 percent CI: 0.5, 1.2; adjusted for age, race, and tubal ligation) but more common among cases who had never used oral contraceptives in comparison with controls (adjusted OR = 1.8, 95 percent CI: 1.0, 3.3). This difference between ever users and never users of oral contraceptives was even stronger when the analysis was limited to women carrying two PROGINS alleles: The adjusted odds ratio was 0.4 for oral contraceptive users and 2.2 for never users. Together, the data of Runnebaum et al. (186) and Lancaster et al. (84) suggest a possible interaction between oral contraceptive use and carriage of the PROGINS allele.

**AR CAG repeat length and ovarian cancer risk**

Two case series (98, 99) examined the association of repeat length with age of disease onset. Levine and Boyd (98) studied 179 Ashkenazi Jewish ovarian cancer patients consecutively diagnosed at a single hospital in New York City (85 BRCA1/2 mutation carriers, 94 sporadic cases). Independent of BRCA1/2 carriage, women who carried a short AR allele, defined as fewer than 20 repeats, were diagnosed an average of 7.2 years (95 percent CI: 2.3, 12.1) earlier than patients who did not carry a short allele (p = 0.0004). In contrast, Menin et al. (99) reported that among 50 women from high-risk families (14 of whom were BRCA1/2 carriers), cases with fewer than 19 repeats had a median age at diagnosis of 58 years, as compared with 52 years for cases with 19 or more repeats (p = 0.03).

Two case-control studies have examined the association of CAG repeat length with ovarian cancer risk (table 4). Spurdle et al. (97) found no association between ovarian cancer risk and AR CAG repeat length in a population-based case-control study. When CAG repeat length was analyzed as a continuous variable, there were no differences between
incident cases and either population controls or controls from a study of monozygotic twins (in which only one twin from each pair was included in the control group) for smaller, larger, and average allele sizes of CAG repeat length, before or after adjustment for age. Moreover, no differences between cases and controls were found when repeat length was analyzed as a dichotomous variable based on median length (22 or more repeats) or based on the length reported to act as a modifier of breast cancer risk (29 or more repeats) (188). However, there was a borderline-significant suggestion that alleles of at least 27 repeats may be weakly protective against ovarian cancer (for cases versus the pooled control group, unadjusted OR = 0.64, 95 percent CI: 0.41, 0.99). This latter finding is consistent with the hypothesis that increased androgen exposure is a risk factor for ovarian cancer (1), because functional studies suggest that longer CAG repeat alleles are associated with decreased AR hormone action (189).

In contrast, in a hospital-based case-control study, Santarosa et al. (40) observed an increase in ovarian cancer risk among women carrying at least one allele with 22 or more CAG repeats (OR = 2.17, 95 percent CI: 1.10, 4.27; adjusted for age). This association was more pronounced in women with a family history of the disease (adjusted OR = 3.52, 95 percent CI: 1.10, 10.47) and in women carrying at least two alleles with 22 or more repeats (adjusted OR = 3.45, 95 percent CI: 1.42, 8.37) (40). Interestingly, 18 of the 27 tumors (six hereditary and 21 sporadic) examined showed preferential expression of the long AR allele, with five of the six hereditary tumors expressing the long allele. Thus, while these data do not support a role for androgens in the etiology of ovarian cancer, they do support the hypothesis that the AR gene may serve as a tumor suppressor gene.

Although the contradictory findings of these two studies might be attributed to ethnic or environmental differences in ovarian cancer etiology between the two populations, it is likely that the differing study designs contributed to the differing results. In particular, although both studies employed a case-control design, in one study, controls were recruited from the general population (97), while in the other, controls were recruited from women donating blood at the hospital from which the cases were identified (40). However, in both studies, the mean age of the controls was significantly lower than that of the cases. Thus, it is possible that the contrasting findings of the two studies can be attributed to differences in the control populations. In particular, while the distribution of allele lengths was almost identical for both studies’ case groups, the distribution of allele lengths between the two studies’ control groups differed substantially (table 4). Hence, because the biology of ovarian carcinogenesis is likely to be independent of ethnic origin, the differences in allele distributions in the control groups may represent a bias in one of the studies rather than a true ethnic difference in allele frequency.

### AR CAG repeat length, BRCA1/2 carriage, and ovarian cancer risk

Only one study (98) has examined the interaction between BRCA1/2 carriage and AR CAG repeat length. Among the 179 consecutive Ashkenazi Jewish cases, no differences in short, long, or average allele length were found between women with one of the three Ashkenazi founder mutations and women without any founder mutations. This result contrasts with results that have been reported for breast cancer (188), in which AR CAG repeat length modified the age at onset and the risk associated with BRCA1/2 carriage. The finding also does not support in vitro studies showing that in breast and prostate cancer cell lines, BRCA1 binds to the AR in the N-terminal region (where the CAG repeat is found) and serves as a coactivator for the gene (190), possibly playing a role in androgen-induced apoptosis (191).

<table>
<thead>
<tr>
<th>Study</th>
<th>CAGn cutpoint</th>
<th>No. of alleles</th>
<th>No. of cases</th>
<th>No. of controls</th>
<th>Age-adjusted odds ratio</th>
<th>95% confidence interval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spurdle et al., 2000 (97)</td>
<td>22</td>
<td>0</td>
<td>75</td>
<td>194</td>
<td>0.86</td>
<td>0.59, 1.25</td>
</tr>
<tr>
<td></td>
<td></td>
<td>4</td>
<td>149</td>
<td>437</td>
<td>0.86</td>
<td>0.59, 1.25</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2</td>
<td>95</td>
<td>222</td>
<td>1.18</td>
<td>0.78, 1.78</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1 or 2</td>
<td>244</td>
<td>659</td>
<td>0.96</td>
<td>0.68, 1.37</td>
</tr>
<tr>
<td></td>
<td>29</td>
<td>0</td>
<td>308</td>
<td>820</td>
<td>0.86</td>
<td>0.59, 1.25</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1 or 2</td>
<td>11</td>
<td>33</td>
<td>1.06</td>
<td>0.47, 2.38</td>
</tr>
<tr>
<td>Santarosa et al., 2002 (40)</td>
<td>22</td>
<td>0</td>
<td>27</td>
<td>35</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>1</td>
<td>57</td>
<td>47</td>
<td>1.7</td>
<td>0.82, 3.53</td>
</tr>
<tr>
<td></td>
<td></td>
<td>2</td>
<td>37</td>
<td>21</td>
<td>3.45</td>
<td>1.42, 8.37</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1 or 2</td>
<td>94</td>
<td>66</td>
<td>2.17</td>
<td>1.10, 4.27</td>
</tr>
</tbody>
</table>
LABORATORY TESTING

**PGR gene**

Early genotyping studies (66) used Southern blot analysis of TaqI-digested genomic DNA hybridized with a PGR cDNA probe. In more recent studies, undigested genomic DNA from peripheral blood leukocytes or banked tissue specimens has been amplified by polymerase chain reaction (PCR). In several studies (66, 84, 85, 186, 192), the region flanking the Alu insertion was amplified. Alleles lacking the insertion appear as smaller bands compared with alleles with the insertion (175 base pair fragments vs. 481) when resolved on agarose gel. Spurdle et al. (185) used the Sequence Detection System allelic discrimination assay (PE Applied Biosystems, Foster City, California) to detect the G and T alleles of the exon 4 Val660Leu polymorphism. Tong et al. (187) used fluorescein-labeled PCR primers to amplify DNA fragments containing the polymorphic sites in exons 4 and 5. They then designed 5-biotin-labeled probes to hybridize either to the wild-type PCR product or the polymorphic PCR product. Allele detection was performed with the ViennaLab Universal Gene Mutation Detection Kit (ViennaLab Labordiagnostika GmbH, Vienna, Austria), in which denatured PCR product is added to oligonucleotide-specific streptavidin-coated wells. The captured oligonucleotides for the polymorphisms in exons 4 and 5 hybridize specifically with either wild-type or polymorphic PCR products, generating genotype-specific color signals. No data on the sensitivity, specificity, or positive and negative predictive values of any of the PROGINS assays have been presented. Moreover, there are no data on the clinical validity of any of these assays.

**AR gene**

Molecular methods for determining AR CAG repeat length were summarized by Nelson and Witte (89). Briefly, PCR is utilized to amplify the CAG trinucleotide repeat in exon 1 using primers that are labeled with [γ-32P]-adenosine triphosphate. The amplified products are then size-separated and analyzed on a denaturing polyacrylamide sequencing gel. The number of repeats can be determined by comparing the gel band to a series of CAG size standards. More recently, fluorescein-labeled primers have been used and the sizes of the PCR products have been determined automatically (97). No data on the sensitivity, specificity, or positive and negative predictive values of the CAG repeat assays have been presented, although Nelson and Witte stated that because “the primers for this test are designed specifically for the CAG repeat,... the sensitivity and specificity are extremely high” (89, p. 888). No data on the clinical validity of the CAG repeat assay have been presented.

POPULATION TESTING

There is insufficient evidence to justify testing for the PROGINS, the +44C/T and +331G/A PGR polymorphisms, or the AR CAG trinucleotide repeat in a screening program for ovarian cancer in the general population. Neither is there sufficient evidence to justify testing for these polymorphisms in a screening program for high-risk women, including BRCA1/2 mutation carriers.

OTHER POTENTIAL PUBLIC HEALTH APPLICATIONS

At this time, the data are insufficient to support any public health recommendations.

CONCLUSIONS AND RECOMMENDATIONS FOR RESEARCH

The mounting evidence for a role of both progestins and androgens in ovarian cancer supports the hypothesis that polymorphisms in the PGR and AR genes may act as risk factors for ovarian cancer and/or as modifiers of risk associated with exposure to hormonal factors. However, the data thus far have been inconclusive. Only two studies have examined the association of the AR CAG repeat with ovarian cancer, with contradictory findings. As was discussed above, differences in the study designs may explain these disparate findings. This suggests a need for large, well-designed studies specifically aimed at addressing the association of the polymorphism with ovarian cancer. Additionally, more research is needed to understand the AR CAG polymorphism and its interaction with known risk factors and protective factors, including oral contraceptive use, parity, hormone replacement therapy, and BRCA1/2 mutation status.

While there have been a greater number of studies on PROGINS and ovarian cancer, the results thus far have been predominantly negative. Although the lack of an association may be real, it is possible that methodological issues, such as small sample sizes, may be obscuring any true association. In addition, the association of PROGINS with a subset of women not using oral contraceptives and with those carrying a BRCA1/2 mutation is intriguing and underscores the need for further investigation into the gene-gene and gene-environment interactions that may partially explain the etiology of ovarian cancer.

In addition to large-scale, population-based studies examining the AR CAG repeat and PROGINS as independent risk factors and as risk-modifying factors for ovarian cancer, studies of emerging polymorphisms in these genes are also needed. Notably, the four recently identified PGR polymorphisms (S344T, G393G, +44C/T, and +331G/A) (65) warrant further investigation, especially because the S344T and G393G polymorphisms are located in the coding region of the gene and the +331G/A polymorphism, which has been found to be associated with an almost twofold increase in risk of endometrial cancer (65), favors increased receptor transcription. In particular, the +331G/A polymorphism is 3′ of the PGR-A and -B transcriptional start sites and favors production of the B isoform (65). Highly malignant forms of ovarian cancer have been correlated with overexpression of PGR-B (193). An association with the +331G/A polymorphism is therefore plausible.

This review has focused on common polymorphisms in the AR and PGR genes. However, polymorphisms in genes along the sex steroid biosynthesis and metabolism pathways also warrant investigation as ovarian cancer risk factors, either alone or, more likely, in combination with lifestyle/
Environmental exposures and other genetic polymorphisms. In particular, polymorphisms in the estrogen receptor gene as well as in enzymes involved in the conversion of cholesterol to progesterone, androgens, and estrogens must be considered (figure 1). To date, only a handful of studies have examined the association of ovarian cancer with single polymorphisms in enzymes involved in this pathway (194–197), and no studies have examined the interaction of several of these polymorphisms together or between these polymorphisms and environmental exposures. Moreover, only one study has examined the association of genotypes with specific histologic subtypes of ovarian cancer (197). The results of these few studies have been mostly negative; only one study reported a significant association between carriage of the cytochrome P-450 17A2 variant and ovarian cancer (OR = 1.86, 95 percent CI: 1.26, 2.75) (197). The increased risk was most apparent in women over age 50 years and in women with invasive serous carcinoma. The same investigators reported an inverse association with carriage of a valine/methionine variant of the catechol-0-methyltransferase gene, especially for women with mucinous tumors (197).

Investigations of multiple polymorphisms in the steroid metabolism pathway are critical, because the high degree of interaction among these gene products, such as the cross-talk between the estrogen receptor and both AR (198) and PGR (199), makes it is unlikely that any one polymorphism alone will confer a substantial individual risk of ovarian cancer. As an example of the effect of multiple polymorphisms in this pathway on cancer risk, one recent study showed that although a polymorphism in the estrogen receptor gene was not a risk factor for prostate cancer, it substantially modified the risk of prostate cancer associated with a short AR CAG repeat (200).

Because the steroid hormone system both influences and is influenced by the insulin and insulin-like growth factor pathways (201–204), these latter pathways and the factors affecting them must also be considered. For example, polymorphisms in insulin-like growth factor I and its binding proteins may alter the availability of insulin-like growth factors (205, 206), which in turn can alter steroid hormone levels (202–204).

Hence, researchers must consider not only the individual effects of genetic polymorphisms but also the joint effects of several genes interacting. Moreover, because an environmental and lifestyle factor, such as alcohol drinking, may exert its effect on both the sex steroid and insulin-like growth factor pathways, genotype combinations must also be considered in conjunction with such factors.

These studies should include ethnically diverse populations in order to capture data on potential lifestyle and cultural factors, as well as other genetic factors, that may modify risk. For identification of specific risk modifiers, the PGR and AR polymorphisms should be examined in combination with specific hormonal exposures, such as oral contraceptive use and hormone replacement therapy regimens. Additional putative risk modifiers include hormone-altering host and dietary/lifestyle factors. Examples of such host factors include body mass index and central obesity, which correlate with hormone levels, especially androgen levels (25). Lifestyle factors that may alter circulating hormone levels include the use of alcohol and certain supplements (such as soy). Alcohol intake has been shown to alter progestin and androgen levels in both oral contraceptive users and nonusers (207).

In addition, detailed data on the timing of host and lifestyle factors, such as weight throughout the life span, should be obtained in order to identify critical time periods in which exposure to certain factors could modify the risk of ovarian cancer associated with the AR or PROGINS polymorphisms. Similarly, detailed data on exposure levels should be recorded in order to identify potential threshold effects.

More advanced approaches to identifying those polymorphisms involved in ovarian cancer are also warranted. In particular, knowledge of the haplotype map will enable researchers to focus on identifying those functional polymorphisms that influence risk, age at onset, clinical course, and response to treatment. In addition, more advanced analytical techniques aimed at uncovering higher-order interactions (208) will prove useful in increasing our knowl-
edge and understanding of the complex interactions between multiple genes along a single pathway, such as the steroid synthesis pathway, or along related pathways, such as the insulin and insulin-like growth factor pathways. These techniques will probably apply to interactions with environmental and lifestyle exposures as well.

In conclusion, although currently the data do not support a definite role for the AR CAG and PROGINS polymorphisms in ovarian cancer etiology, there is sufficient evidence of a possible association to warrant further investigation. Studies collecting detailed data on lifestyle and host factors throughout the life span, together with additional genetic data on not only the steroid hormone pathways but also related pathways such as those of the insulin-like growth factors, are needed. Collection of such detailed data in large, diverse populations will enable scientists to identify more precisely the individual and joint roles of genetic factors and environmental exposures in the etiology of ovarian cancer.

ACKNOWLEDGMENTS

This research was supported by grants K07-CA80668 and R03-CA92776 from the National Cancer Institute and grant DAMD17-001-0569 from the US Department of Defense (Ovarian Cancer Research Program).

The authors thank Dr. Jeffrey L. Eppinger for his comments on this work. They also thank Dr. Julia Greer and Randi E. Koenig for their help with the manuscript.

REFERENCES

14. De Pergola G, Triggiani V, Giorgino F, et al. The free testosterone to dehydroepiandrosterone sulphate molar ratio as a...


51. McKenna NJ, Kieback DG, Carney DN, et al. A germline TaqI restriction fragment length polymorphism in the proges-


APPENDIX

Internet Sites

Ovarian cancer

American Cancer Society: http://www.cancer.org
National Ovarian Cancer Coalition: http://www.ovarian.org/
Ovarian Cancer National Alliance: http://www.ovariancancer.org/
Gilda Radner Familial Ovarian Cancer Registry: http://www.ovariancancer.com/default.asp

Genetic databases

The Androgen Receptor Gene Mutations Database: http://www.mcgill.ca/androgen
Human Gene Mutation Database: http://archive.uwcm.ac.uk/uwcm/mg/hgmd0.html
GeneCards: http://bioinfo.weizmann.ac.il/cards/